GC
NRIX icon

Grace Capital’s Nurix Therapeutics NRIX Stock Holding History

Grace Capital’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,727
Closed -$190K – 152
2021
Q3 		$190K Buy
6,727
+2,158
+47% +$66.6K 0.12% 150
2021
Q2 		$121K Buy
4,569
+2,106
+86% +$61.8K 0.08% 154
2021
Q1 		$77K Buy
+2,463
New +$93.2K 0.05% 195

Other funds holding NRIX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Grace Capital's NRIX Position: Q4 2021 in Review

Grace Capital sold out of Nurix Therapeutics (NRIX) in Q4 2021, closing a stake of 6,727 shares — an estimated $190K sold.

Grace Capital first reported a position in NRIX in Q1 2021 and held it in 3 quarters. The position peaked at $190K in Q3 2021. 125 funds tracked by Wall St. Rank hold NRIX as of Q4 2021.

  • Grace Capital reported no remaining Nurix Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Grace Capital sold 6,727 Nurix Therapeutics shares in Q4 2021, an estimated $190K.
  • Grace Capital first reported a position in Nurix Therapeutics in Q1 2021 and held it in 3 quarters.
  • Grace Capital's Nurix Therapeutics position peaked at $190K in Q3 2021.
  • 125 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2021.

Based on Grace Capital's 13F filing for Q4 2021, filed 2 Feb 2022.